行情

CLBS

CLBS

Caladrius
NASDAQ

实时行情|Nasdaq Last Sale

3.010
+0.100
+3.44%
已收盘, 16:00 01/28 EST
开盘
2.900
昨收
2.910
最高
3.030
最低
2.900
成交量
5,333
成交额
--
52周最高
5.44
52周最低
2.000
市值
3,130.38万
市盈率(TTM)
-1.7087
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLBS 新闻

  • 南非亿万富翁说非洲人爱特朗普 被痛批后道歉
  • 新浪财经.3小时前
  • 日产在美销量大减 将向当地老员工提供工龄买断计划
  • 新浪财经.4小时前
  • 澳大利亚科学家成功培育出新型冠状病毒样本
  • 中国新闻网.4小时前
  • 韩国将新冠肺炎纳入甲级传染病管理
  • 新浪财经.4小时前

更多

所属板块

生物技术和医学研究
+0.97%
制药与医学研究
+0.58%

热门股票

名称
价格
涨跌幅

CLBS 简况

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company that provides cell therapies for cardiovascular and autoimmune diseases. The Company’s product candidates include three developmental treatments for cardiovascular diseases based on its classification determinant34+ (CD34+) cell therapy platform. Its CLBS12 product candidate is a recipient of a SAKIGAKE designation in Japan and advanced therapy medicinal product classification (ATMP) in Europe. Its CLBS16 product candidate is being developed for the treatment of coronary microvascular dysfunction (CMD). Its CLBS14 product candidate is a phase III ready clinical program in no option refractory disabling angina. CLBS14 is a recipient of a regenerative medicine advanced therapy (RMAT) designation in the United States. It also has an autoimmune product candidate, CLBS03, which is being developed for the treatment of type I diabetes.
展开

Webull提供Caladrius Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。